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Background: HIV persists as a public health emergency in South Africa, especially among women of childbearing
age. In response to the HIV epidemic, the Joint United Nations Programme on HIV/AIDS has put forth the 90–90-90
global goals to achieve an AIDS-free generation by 2020. This goal aspires to have 90% of people living with HIV
diagnosed; 90% of those who test positive on sustained antiretroviral therapy (ART); and 90% of those on ART be
virally suppressed. Ensuring access to ART is an important first step in reducing HIV incidence, especially among
vulnerable populations such as women who use substances and bear the burden of HIV in South Africa. Additionally,
alcohol and other drug (AOD) use and exposure to gender-based violence are associated with increased risk of HIV
infection and reduced adherence to ART. However, no research has estimated ART adherence rates for women who
use substances in South Africa since the government approved the provision of ART to all people living with HIV.
Methods: The Women’s Health CoOp (WHC) is an evidence-based, woman-focused, behavioral intervention that
addresses the intersecting risks of AODs, sex behaviors, and violence and victimization, with the primary goal of
increasing skills and knowledge to reduce substance abuse and HIV risks and to improve ART adherence. The WHC has
been packaged for further dissemination. This article describes the study protocol used to assess the feasibility and
acceptability of implementing the WHC intervention into standard of care in Cape Town health clinics and substance
abuse rehabilitation centers to reduce HIV risk behavior and increase ART adherence among women who use
substances and are living with HIV.
Discussion: Because few of the interventions that demonstrate efficacy for HIV prevention and ART adherence in
randomized trials are sustainable, studies to adapt and test intervention variations are needed to determine the best
strategies for implementing them in real-world, high-risk settings. However, implementation in real-world settings
presents challenges. Consequently, intervention developers should consider the strengths and limitations of their
anticipated implementation setting by engaging with key stakeholders before, during, and after the adaptation and
implementation process when developing and attempting to scale-up interventions.
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Mounting evidence indicates that large-scale provision
of antiretroviral therapy (ART) is key to arresting the
HIV epidemic [1]. Two key studies have demonstrated a
decreased incidence of HIV among seronegative partners
when their HIV-positive partners initiate ART as soon as
they receive their diagnosis [2], and lower HIV preva-
lence among persons living in areas where there is
greater ART use among people who are HIV-positive
[1]. In light of the rigorous trials highlighting the
overwhelming need to extend distribution of ART, in
2015 the World Health Organization revised its HIV
treatment guidelines, recommending that all people
living with HIV receive ART regardless of CD4 count
[3]. Also, the Joint United Nations Programme on
HIV/AIDS (UNAIDS) has put forth the 90–90-90
global goals to achieve an AIDS-free generation by
2020 [4]. This goal states that 90% of people living
with HIV are diagnosed, 90% of those who test posi-
tive for HIV are on sustained ART, and 90% of those
on ART will be virally suppressed [4].
Ensuring access to ART is an important first step
in reducing HIV incidence. However, numerous bar-
riers exist between access to ART and actual use and
adherence. These barriers often relate to behavioral
factors that increase a person’s risk of HIV acquisition
or reduce their agency to access or adhere to their
medications. In particular, previous research demon-
strates that transactional sex, alcohol and other drug
(AOD) use, and exposure to gender-based violence
(GBV) are associated with increased risk of HIV
infection and reduced ART adherence [5–12]. To curb
the incidence of HIV and ensure that people living
with HIV are able to live longer and healthier lives, it
is important to implement evidence-based interven-
tions (EBIs) that address gender context and reduce
risk behaviors to help improve ART uptake and
adherence. Implementation science provides a frame-
work for determining the best strategies for integrat-
ing EBIs into standard healthcare practice and
assessing their feasibility, acceptability, and effective-
ness as they are rolled out in real-world settings [13].
In this article, we describe the protocol for a study
funded by the U.S. National Institute on Alcohol Abuse
and Alcoholism to assess the feasibility and acceptability
of implementing an evidence-based, gender-focused
intervention—the Women’s Health CoOp (WHC) pro-
gram—in government health clinics that provide HIV
testing and counseling (HTC), ART, tuberculosis (TB)
treatment, and antenatal care; and in substance use re-
habilitation (rehab) centers in South Africa. The project
also assesses the effectiveness of the WHC among the
women participants and the sustainability of the pro-
gram in these settings over time.A focus on women and the 90–90-90 goal in South Africa
South Africa is the epicenter of the HIV epidemic; evi-
denced by the fact that 1% of the world’s population lives
in South Africa, but about 17% of all persons living with
HIV (5.6 million people) reside there [14]. Extremely
vulnerable, impoverished women living in South African
disadvantaged communities face myriad risks for HIV.
For example, historically South Africa has had a patri-
archal culture that fueled women’s social, legal, and eco-
nomic disempowerment [15]; which, in turn, increases
their risk of HIV infection. Research from over a decade
in Pretoria has demonstrated that HIV prevalence
remained stable among women who engage in sex work
at about 68%, but increased among women who do not
engage in sex work who use substances, including alco-
hol, from 34% in 2004–2007 to 47% in 2012–2014 [16].
Furthermore, recent research with women who engage
in sex work and women who do not engage in sex work
in Pretoria indicated that only 16% of women who were
HIV-positive were on ART [17].
Achieving the 90–90-90 goal in South Africa will
require reaching vulnerable populations, such as women
who engage in sex work and/or substance use, and test-
ing them for HIV, linking them to ART, and retaining
them in care. Gender-focused, behavioral interventions
that address multiple risk-taking behaviors can facilitate
ART initiation and retention. However, contextual and
structural factors—such as lack of transportation, food
insecurity, myths and beliefs regarding HIV, and navigat-
ing the public health system—create barriers that
interfere with ART initiation and adherence [18]. Add-
itionally, many vulnerable South African women experi-
ence GBV or AOD use (or a combination of these
factors), which can contribute to HIV risk [9–12, 19].
Furthermore, multiple barriers exist regarding access to
and the use of substance use rehab in South Africa,
which is further complicated by the scarcity of affordable
programs and a lack of knowledge regarding how to
access the limited programs that are available [20].
Addressing the nexus of substance use, gender-based
violence, and HIV risk
Since 2001, our research team has developed and
adapted the WHC, an evidence-based, woman-focused,
behavioral HIV prevention intervention that reaches
high-risk, hard-to-reach women in various contexts. The
WHC addresses the intersecting risks of substance use,
sex behaviors, and violence and victimization, with the
primary goal of increasing skills and knowledge to re-
duce substance abuse and HIV risks. The original
Women’s CoOp intervention was conducted in the
United States and was named a Centers for Disease
Control and Prevention “best-evidence” behavioral inter-
vention for HIV prevention [21]. Since its inception, it
Wechsberg et al. BMC Women's Health  (2017) 17:85 Page 3 of 11has been adapted from previous iterations to new popu-
lations and settings in North Carolina, Rhode Island,
Massachusetts, Russia, the Republic of Georgia, and sev-
eral regions in South Africa [15, 22–27]. To promote the
use of EBIs in Africa, the U.S. Agency for International
Development (USAID) included the first adaptation of
the WHC intervention [22] in its Compendium of Gen-
der Studies in Africa [28].
The WHC is grounded in empowerment and feminist
theory to emphasize the inverse relationship between
substance abuse and personal power and that reduced
personal power leads to increased risk behaviors and
victimization. Two intervention sessions are held
approximately 1 week apart, with each session lasting
about 1 h. Sessions can be conducted in groups, work-
shops, or one-on-one individual sessions. Key elements
of the sessions educate participants about the risks of
AOD use and how AOD use and sexual risk relate to
HIV for women. The WHC also teaches risk-reduction
methods such as proper condom use, sexual negotiation,
and violence prevention strategies. Women also role-
play and rehearse how to use male and female condoms
correctly, as well as condom negotiation. At the end of
the second session, participants create goals to reduce
personal risk. Intervention staff also provide referrals to
services and linkages to care.
Following numerous trials in which the WHC demon-
strated efficacy, the program was packaged to facilitate
widespread dissemination and implementation. The
intervention package includes a brief marketing over-
view for decision-makers and materials for intervention-
ists. It also includes a complete set of intervention
materials, the curriculum, and an outreach manual with
instructions related to reaching hard-to-reach vulnerable
women. Based on the principles of translation frame-
works, such as the RE-AIM model [29], the next logical
step would be to evaluate the implementation of the
packaged WHC in real-world clinical care settings. In
this implementation science project, the WHC interven-
tion will be implemented by clinic staff in healthcare
clinics and substance use rehab centers as part of stand-
ard of care among women living with HIV who use sub-
stances. The WHC will address women’s multiple risk-
taking behaviors and promote adherence to ART.
Implementation of the WHC
Prior research suggests the need to adapt and modify
evidence-based programs to make them more flexible
and amenable to scale-up in real-world settings [13].
The adaptation and modification steps need to be moni-
tored and evaluated to ensure that they support contin-
ued fidelity to the overall model and lead to outcomes
that are similar, but not necessarily identical, to efficacy
trials. A framework for wider scale-up that leads toadoption of an innovation in real-world settings must
consider multiple, nested levels—such as patient, pro-
vider, setting, organization, and environment—at which
implementation and evaluation occur [30]. The approach
posits that successful implementation begins with an
evidence-based practice, in this case the WHC, to which
there is initial training of clinical staff followed by pre-
liminary and setting-specific modifications, then adop-
tion and evaluation of multilevel outcomes. The process
begins with formative work to identify any potential bar-
riers to adoption and use of the WHC. Modification, im-
plementation, and evaluation are iterative and interactive
processes that form a feedback loop for monitoring ser-
vice delivery, intervention refinements, implementation
strategies, evaluation protocols, and quality of care in a
staged progression prior to full implementation. As part
of this project, these multiple steps will be implemented
to refine and test the WHC program for wide-scale use
in healthcare clinics and substance use rehab centers.Methods
Aims and objectives
The overarching goal of this project is to assess the
acceptability and feasibility of implementing the WHC
in usual care settings and to assess the effectiveness of
the intervention as it is implemented. The project has
three specific aims. Aim 1 is to undertake qualitative
data collection to develop, implement, and assess the
appropriateness of a marketing plan or a recruitment
strategy to facilitate entry into HTC/healthcare clinics
and substance use rehab centers for the implementation
of the WHC. Aim 2 is to test and evaluate a modified
WHC program that has inputs from the first phase;
evaluation will use a stepped-wedge design across the
health clinics that provide HTC, ART, TB treatment, and
antenatal care matched with substance use rehab pro-
grams to determine implementation outcomes (appro-
priateness, acceptability, adoption, cost, fidelity,
feasibility, and sustainability) and service outcomes
(comprehensiveness of services and timely service link-
ages). Aim 3 will assess the impact of the WHC program
on patient outcomes at 6-month follow-up.Setting
The WHC is being rolled-out sequentially in four HTC/
healthcare clinics and four outpatient substance use
rehab centers located in selected disadvantaged commu-
nities (townships) in Cape Town. These sites were iden-
tified and approved by the City of Cape Town Health
Department. Each HTC/healthcare clinic was paired
with a substance use rehab center based on geographic
proximity, and each pair was randomized by computer
into four succeeding 6-month implementation cycles
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ultaneously at the paired sites.
Study design
The overall study uses a stepped-wedge design, as shown
in Fig. 1. This design lends itself to implementation
science research adaptation and mixed methods [31]. It
also has several logistical and scientific advantages, as it
involves incremental execution of the intervention;
allows continued measurement of key process and out-
come indicators; accommodates periods of feedback
loops; allows for retrospective evaluation of sustainabil-
ity; and accounts for temporal trends, such as changes in
ART regimens (i.e., universal coverage) or funding for
healthcare that may impact implementation. Our itera-
tive approach will incorporate lessons learned at each
step, making the integration process more efficient and
conducive to identifying aspects of the clinic environ-
ment and the WHC that are acceptable, scalable, and
sustainable.
As depicted in Fig. 1, this study has 4 cycles spanning
several years. Each implementation cycle of the WHC
program lasts 6 months. Based on the findings from
each cycle, we undertake a brief formative “lessons
learned” evaluation. These periods between cycles in-
form backward- and forward-implementation strategies
through mixed methods of brief staff surveys and focus
group discussions (FGDs), allowing for modification ofFig. 1 Implementation science study design for the Women’s Health CoOpthe WHC while preparing for training in the next cycle.
Pre-, mid-, and end-of-implementation FGDs are con-
ducted to inform the modifications, including training
materials, curriculum, and implementation data collec-
tion. Pre-implementation FGDs involve setting the stage
for entry into the clinics, so that barriers and challenges
can be addressed. Mid-implementation FGDs explore
initial results and help determine if additional modifica-
tions to the intervention are needed. End-of-
implementation FGDs with clinic staff and patients
explore satisfaction with the intervention and concerns
with the program’s sustainability. This format provides
back-and-forth feedback and dialogue with clinic staff
on the implementation processes and outcomes for fur-
ther refinement. Consequently, the clinics randomized
to Cycle 1 will have the longest post-intervention obser-
vation period, with implementation sustainability mea-
sured through fidelity checks and quantitative surveys.
Conversely, based on lessons learned throughout the
earlier cycles, sites in Cycle 4 benefit from an interven-
tion that is more refined and in the most scalable form.
Study procedures
Data collection: formative phase
The formative phase was completed in November 2014.
During this phase, we engaged our Community Collab-
orative Board (CCB)—a group of key stakeholders and
policymakers that have been key collaborators on theprogram
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local department of health, and women who use sub-
stances from the target communities—to develop a mar-
keting plan and engagement strategy that addressed the
potential challenges and barriers to integrating the
WHC into existing HTC/healthcare clinics and sub-
stance use rehab centers in Cape Town. These infor-
mants helped identify potential challenges to integrating
the WHC into usual care settings. Methods of engage-
ment included expert interviews with regional and
local policymakers and FGDs with staff from HTC/
healthcare and substance use rehab centers. Informa-
tion from the formative phase led to important adap-
tations to the WHC model. In particular, we were
able to identify the need to implement extensive re-
cruitment strategies in the community because many
of the women who were living with HIV and using
substances were not currently visiting health facilities
[32].
Data collection: implementation phase
We are using a Type 2 hybrid trial design that empha-
sizes both clinical effectiveness and implementation out-
comes, with the eventual goal of more rapid translation
and uptake to usual care settings [33]. Consequently,
data collection will include repeated measures at the
clinic and patient levels.
Clinic-level data collection
Prior to integrating the modified WHC program into
the facilities, clinic staff are identified and presented
with information on the WHC intervention. They
then complete a survey to assess organizational readi-
ness for change, including perceived barriers to
change, acceptability, feasibility, and appropriateness
of implementing the WHC in these facilities. This
survey is then re-administered at the end of the
implementation cycle. This process will be repeated at
subsequent cycles. To assess long-term sustainability
of the WHC, we will complete a brief checklist
6 months after the end of each cycle. These post-
intervention sustainability checks will be repeated
after each cycle such that Cycle 1 facilities have the
longest post-intervention observation period on
sustainability.
Patient-level process and data collection
The patient-level study includes a baseline visit and a 6-
month follow-up visit to evaluate intervention effective-
ness. Eligibility criteria include (1) being between the
ages of 18 and 45 years, (2) self-reporting use of at least
one drug, including alcohol, at least weekly during the
previous 3 months, (3) reporting unprotected sex with a
male partner in the past 6 months, (4) having a positiveverifiable HIV test result, (5) reporting the intention to
remain in the area for at least the next 6 months, (6)
providing contact information, and (7) being willing to
participate in alcohol and other drug screening.
A field team hired by Kheth’Impilo, the local nongov-
ernmental implementing partner, leads the outreach and
data collection activities. Trained outreach workers oper-
ate as recruiters of women within clinics and surround-
ing communities and track eligible women for the study,
while data capturers collect patient-level data from
participants at the baseline and 6-month follow-up
appointments. These are well-established methods from
other studies conducted in the region [34, 35]. Once
participants are enrolled, clinic staff trained and certified
in the WHC offer the adapted intervention to all women
enrolled and to other women in their clinics who may
be interested in participating, so as to operate as a real-
world setting.
At each data collection visit, a member of the
research/implementing team administers a face-to-face
interview using a secure tablet with skip patterns and
quality-control checks programmed into the interview.
The study instrument includes measures of socioeco-
nomic status, sex risk behaviors, AOD use, substance
abuse treatment readiness, ART use and barriers to use,
and other self-reported clinical outcomes such as TB
and symptoms for sexually transmitted infections.
Biological data are obtained from a urine specimen
tested for pregnancy and metabolites for recent drug
use. Participants also undergo a breathalyzer test for
recent alcohol use. The same measures are collected at
6-month follow-up.
HIV testing is not part of the research because it is
performed by clinic staff as part of standard clinic opera-
tions. As proof of HIV-positive status, participants must
provide a clinic-issued document such as an antiretro-
viral (ARV) card or ARV medication with identifiable
data linking to the participant, or they must consent the
research staff to access their hospital records for their
results. Viral load is also collected at baseline and 6-
month follow-up from the South African National
Health Laboratory Service (NHLS) database in the
clinics. Viral load testing is also part of the standard of
care and the clinics routinely perform HIV viral load
testing 6 months after a patient begins taking ART and
then 12 months later; however, these intervals may vary
by clinic. Viral load test information will be used to val-
idate self-reported ART adherence.
In each cycle, the objective is to enroll 120 women (60
from a HTC/healthcare clinic and 60 from a substance
use rehab center) for a sample total of 480, and to follow
each enrolled participant at 6 months, with an expected
follow-up rate of 90%. At the end of the 6-month
follow-up period, we will assess effectiveness of the
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whether women reduced their AOD use, are adhering to
their ARV regimen, have reduced their sex risk behav-
iors (e.g., using a condom at every sex act; less transac-
tional sex), and have experienced less to GBV. At the
end of each cycle, we will conduct FGDs with a sub-
sample of women who participated in both workshops
of the intervention and completed their 6-month follow-
up appointment. These study activities will enhance our
understanding of women’s satisfaction with the WHC
program and suggest modifications to the program for
broader acceptability and implementation that will be in-
corporated into the next cycle.
Data management and quality assurance
To protect confidentiality, the study assigns each partici-
pant a unique study identification code (ID). This ID is
the only link between the behavioral and biological data
and the identifying information collected for locating
participants for their follow-up interviews. Locator infor-
mation is stored separately from other data in a double-
locked file cabinet in a locked room with restricted
access. Data collection for this study is conducted by
highly trained, local implementing staff that develop a
rapport with the study participants to engender trust
and elicit the most accurate data possible. Data are
transmitted each day from the field site to secure servers
in the United States. The US-based data manager
reviews additional automated quality control checks that
the software generates each day. If any critical inconsist-
encies are noted, the data manager contacts the field
project manager who works with the field staff members
to resolve the inconsistencies. The principal investigator,
other members of the research team, and the field staff
also receive daily activity reports.
Adverse events and severe adverse events
Adverse events (AEs) or severe adverse events (SAEs)
related to data collection or any other research activities
are reported to the principal investigator and co-
investigators within 24 h, and the funding agency and
the Institutional Review Board within 48 h, with appro-
priate action taken immediately. HTC/healthcare clinics
and substance use rehab centers follow their standard
procedures, including distressed respondent procedures,
for any AEs related to the participants that they treat.
The study does not interfere with the clinics’ standard
operating procedures.
Evaluation of outcomes
Clinic operations and implementation indicators
Prior to the initiation of each cycle, the master trainer
from Kheth’Impilo trains the clinic staff on implementa-
tion of the WHC program for 2 weeks prior toimplementation launch. Clinic staff involved with the
WHC receive intensive, manual-supported training on
the WHC and must role-play and rehearse the protocol.
Following training, the trainer provides ongoing moni-
toring, coaching, and mentorship for the 6-month
follow-up period. The implementing research staff
receive training on data collection and methods; clinical
manifestations of drug abuse and HIV; issues surround-
ing confidentiality, especially within the communities
where there is concern about local gossip as reported
from the formative activities; to ensure that participants
are not intoxicated; and to address any HIV-related
concerns during research activities [32].
During each cycle and between cycles, we will quanti-
tatively and qualitatively assess barriers and facilitators
to the WHC implementation at the clinic level from the
perspectives of interventionists, administrators, and
other healthcare providers involved in the WHC pro-
gram. Modifications identified through the cyclical as-
sessments are incorporated into the training of trainers'
materials to support continued adaptation and refine-
ments for long-term sustainability. To assess costs, clinic
staff interventionists will record the number of minutes
spent on various WHC-related tasks, such as prepar-
ation, conducting intervention sessions, and referrals.
To measure the implementation processes and out-
comes, we will undertake quantitative data collection
with providers and review implementation records to
assess fidelity of program implementation. Fidelity
checks on a random basis will be conducted on the ac-
tual groups conducted. Clinic interventionists and other
clinic staff who interact with patients participate in the
pre-, mid-, and post-implementation FGDs and also
complete the self-administered pre- and post-clinic sur-
veys. We will assess seven implementation outcomes
to determine program success, as proposed by Proc-
tor and colleagues [13]. Not all implementation out-
comes will be assessed across each of the four cycles;
however, the protocol for measuring implementation
outcomes will remain constant at each cycle. Some of
the intervention outcomes will be measured quantita-
tively and others will be measured qualitatively. The
standard implementation outcomes and their meas-
urement methods are outlined in Table 1.
Modifications to protocol
The team has made modifications to the protocol to
strengthen the study design and facilitate implementa-
tion. Table 2 summarizes these changes, which were all
approved by the appropriate ethical boards.
Power
We used the Stata command, steppedwedge [36], which
is based on the equation developed by Hussey and
Table 1 Standard implementation outcomes and their measurement methods
Implementation outcome Description Measurement Data source Time point
Appropriateness The extent to which the WHCa is
congruent with the culture of the
clinic setting
Focus group discussions Clinic staff, community
women, administrators
Formative
Organizational Readiness Texas Christian University
organizational readiness
for change [46]
Interventionists and
administrators
Pre-implementation
Comprehensive Services Linkage
Referrals
Self-report Participants of the WHC 6-month follow-up
Comprehensive Services Linkage
Referrals
Research staff report Clinic and research staff Daily
Acceptability Feedback on the modified WHC Focus group discussions Clinic staff and
administrators
Multiple time points from
mid- to post-implementation
Client satisfaction The Client Satisfaction
Questionnaire (CSQ-8) [47]
Participants of the WHC 6-month follow-up
Adoption Current state of implementation
of the WHC and challenges to
implementing the WHC
Focus group discussions Clinic staff Mid- and post-implementation
Cost Costs associated with
implementing the WHC
Clinic-Patient Contact
form [48]
Clinic staff Throughout the
implementation cycle
Feasibility Exposure to and retention of
the WHC
Number of WHC modules
being delivered
Clinic staff Throughout the
implementation cycle
Coordination of services
related to WHC (e.g., ART)
Percentage of women
who are referred to and
seek out related services
Participants of the WHC 6-month follow-up
Fidelity The extent to which
interventionists are conducting
the WHC as intended
Observer rating forms Research staff Weekly
Sustainability The extent to which the WHC
is being implemented as a
standard of practice
Self-administered survey Clinic staff Every 6 months after
exit from clinic until
end of study
aWHC = Women’s Health CoOp
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between participants’ adherence before and after their
exposure to the intervention, given a sample size that is
feasible and realistic in these clinic settings (n = 480; or
120 participants per cluster). We conducted twoTable 2 Modifications to the protocol and intervention adjustments
Date Amendment
August 2015 Required a digit
to be later verifi
November 2015 Adopted the use
participant’s HIV
November 2015 Allowed the use
to identify locati
August 2016 Added collecting
self-reported AR
August 2016 Added a sustain
sustainability of
abuse needed s
plan used in pre
time limitations;
from the session
clerks and comm
checks cannot aanalyses based on the following parameters: 120 partici-
pants per cluster, 240 observations per cluster, and
power of .80. The first analysis was used to calculate the
detectable difference between participants’ self-reported
percentage of ART adherence during the past month/considerations
al photo-capturing method to document drug and pregnancy tests,
ed by the project manager
of clinic-issued ARV cards and ARV medication as proof of
-positive status in the absence of patient records
of outreach assistants (who are different from the outreach field staff)
ons to reach potential participants.
HIV viral load tests results from participant clinics to validate
T adherence
ability questionnaire to be administered to clinic staff, to monitor
the WHC Intervention Adjustments/Considerations: The drugs of
ome adjustments for the local context from other regions; personalized
vious studies was not found to be feasible because of concerns about
there was not time for case-management or interventionist follow-up
s; transportation and childcare would have to be considered; training
unity healthcare workers such as nurses/clinicians were too busy; fidelity
lways be audio-recorded because of steady intercom usage.
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has estimated the percentage of ART adherence among
South African women who use substances since the gov-
ernment approved the provision of ART to all people
living with HIV, regardless of CD4 count. Consequently,
we based our analyses on a national estimate of the aver-
age percentage of ART adherence in South Africa since
the ART rollout (87%; SD = 17.28). Based on this esti-
mate, we will be able to detect an increase or decrease
in adherence of 4% or greater. Next, we calculated the
detectable difference between the proportion of adherent
(i.e., report 95% or greater adherence or are virally sup-
pressed) participants before and after their exposure to
the intervention. We based this calculation on previous
research that has reported on the proportion of people
who engage in substance use that are adherent to ART
(56%) [38] and national estimates indicating that 55% of
all people living with HIV are virally suppressed [39]. In
regards to self-report adherence, we estimate that we
will be able to detect a difference of 13% or greater.
Similarly, we also estimate that we will be able to detect
a difference of 13% or greater to examine the change in
the proportion of women who are virally suppressed be-
fore and after the intervention.
Analysis
The analysis will treat count outcomes as Poisson
distributed. A number of multilevel factors can impact
the outcomes, including site/clinics, city, time, and the
type of the site (HTC vs. substance use rehab). Because
individuals are clustered within sites and sites are clus-
tered within a city, we need to consider the variance in-
flation factor that results in this clustering. We
considered a number of approaches: using random effects,
fixed effects, or Generalized Estimating Equations (GEE)
considering population-averaged methods. Although a
random effects model for sites seems a natural approach,
we needed to consider fixed effects of the city and of the
site type, which would leave little power left to estimate
the random effects distribution. Consequently, we will also
use two other methods, GEE and the fixed effects model,
to assess sensitivity by comparing the results across these
models.
We will use Stata Release 14 (College Station, TX) and
SAS version 9.2 (Cary, NC). Data will be examined to
determine the extent to which they meet appropriate
distributional assumptions. We will use methods
described by Ecob and Der to identify outliers in longi-
tudinal models and use methods of case downweighting
when extreme cases are identified [40]. Missing data will
be handled using multiple imputation methods [41]. The
patient-level analyses will be organized into three groups
to examine (a) successful reduction of risk behaviors
targeted by the WHC (i.e., effectiveness), (b) patientsatisfaction, and (c) increasing the number of women
receiving ART and adhering to ART, and being admitted
to substance use rehab.
To assess effectiveness, the analysis will compare
changes from baseline to 6-month follow-up on the
amount of alcohol consumption, biological and self-
reported drug use, condom use at last sex, number of
sex partners over the past 6 months, and values from
scales that measure relationship power and communica-
tion. We will start with descriptive analyses, including
measures of central tendency, and dispersion (e.g.,
means, medians, proportions, standard deviations).
Bivariate analysis will include paired t-tests, Wilcoxon
rank-sum, and tabular statistics and the chi-square test.
For multivariable analysis, the xtlogit and xtgee function
will be used to specify random effects or fixed effects,
and will assume that the correlation matrix is exchange-
able. The models will control for other covariates identi-
fied in bivariate analyses or hypothesized a priori (e.g.,
condom use is correlated with substance use). One of
the most important covariates in the model will be mea-
sures of patient satisfaction. Model performance and fit
will be assessed with incremental elimination of vari-
ables, likelihood ratio tests, and changes in the Akaike
information criterion (AIC) and Bayesian information
criterion (BIC) values.
Patient satisfaction analyses will be predominately
descriptive to determine if satisfaction improves with
each cycle, varies by type of clinic, and by participant
characteristics (e.g., alcohol use, pregnancy status).
We assume that the prevalence of patients receiving
or adhering to ART or receiving treatment for substance
abuse are Poisson distributed and increase from baseline
to follow-up. We will use a similar approach outlined in
the effectiveness analysis for bivariate and multivariable
analyses. Variables considered for multivariable analysis
will include patient characteristics, measures of patient
success with the WHC, patient satisfaction, and clinic-
level characteristics (e.g., type of clinic, provider
satisfaction).
Discussion
Multiple EBIs exist to help reduce HIV risks in low- and
middle-income countries. However, only about 14% of
EBIs are ever incorporated into standard practice. For
those 14%, it takes an average of 17 years from the time
they are developed and tested to the time they are
implemented widely [42]. Successful translation of EBIs
into practice must be informed through implementation
science research, which seeks to document the process
of uptake, translation, and implementation of these EBIs
into real-world settings.
This article describes the study protocol for a project
to assess the feasibility and acceptability of
Wechsberg et al. BMC Women's Health  (2017) 17:85 Page 9 of 11implementing the WHC in HTC/healthcare clinics and
substance use rehab centers. This project uses a
stepped-wedge design that permits continued adaptation
and modification of the process to ensure that lessons
learned in each cycle are incorporated to enhance the
sustainability and scalability of the intervention for
broader implementation.
Undertaking these types of projects for implementing
EBIs into new settings is an important goal of future
HIV programs because the evidence on how to imple-
ment efficacious interventions effectively remains scarce
[43]. Implementation research projects, such as this,
may be particularly critical in helping UNAIDS reach its
90–90-90 goal for HIV testing, treatment, and viral sup-
pression. Additionally, projects like this can provide
guidance for how to scale up efficacious programs that
identify women who may be unaware they are HIV posi-
tive, link them to testing and treatment, and support
them to adhere to ART.
Numerous prior interventions that demonstrated effi-
cacy in randomized trials are not scalable or sustainable.
Consequently, undertaking studies to adapt and test var-
iations of these interventions are needed to determine
the best strategies for implementing them in community
care settings within disadvantaged communities in South
Africa. However, as noted, real-world settings present
practical problems and most care providers need to be
convinced that these interventions will improve care
without increasing the burden on the healthcare team.
Consequently, intervention developers should assess the
strengths and limitations of their anticipated implemen-
tation setting when developing and attempting to imple-
ment and scale-up interventions.
One particularly important aspect of this project is the
marketing campaign to achieve buy-in from providers
and patients prior to implementing the intervention.
Clinical staff recognize that to reach the 90–90-90 goal
more women need to get tested, as many are unaware of
their serostatus and there are many new incident cases
among women of childbearing age [17]. However, one
thing that some care providers and staff may not have
considered is that substance use in South Africa is a ser-
ious problem, especially alcohol use during pregnancy
[44, 45]. These interacting forces, along with high preva-
lence of GBV within relationships and communities, ne-
cessitate a gendered intervention for women, especially
women living with HIV. Our WHC marketing materials
highlight that HIV, AOD, and GBV are critical problems
for women and introduces the WHC intervention as a
program that addresses these issues to promote adher-
ence to ART. Clinic staff want good clinical outcomes
and such an intervention could be a win-win for all if
implemented successfully, especially if women felt com-
fortable discussing these issues.South Africa has a long history of class, ethnic, and
gender inequality. Many of these disparities are still
prominent in the communities where these women live,
and this project presents an opportunity to help em-
power women through an intervention offered in a usual
care setting if successfully sustained.
Trial status
The study is now in the field, with further modifications ne-
cessary. The first modification involved identifying women
who use substances and are living with HIV, because many
women are unwilling to admit that they are living with HIV
or that they are using substances. Additionally, they may be
unwilling to be tested because they have been treated
poorly and are afraid to go to health services. Consequently,
to increase access to healthcare services for study partici-
pants, the research team had to provide training to clinic
staff and outreach workers to educate them about stigma
surrounding HIV and substance use. Further, the electronic
database systems to verify HIV status for those who had
already tested were out of date (e.g., some names and dates
of birth were not accurate based on the information given
by the participants). Consequently, the research team
established alternative protocols to verify HIV status.
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